Vaccine Development Against Novel Breast Cancer Antigens
Abstract
The aim of these studies were to produce new antigens overexpressed in breast cancer; to immunise mice with these, particularly using new modes of immunisation including oxidised mannan and to measure the ensuing antibody and cellular responses and ultimately determine the effect of using multiple antigens on tumour growth in mice. In the first year of the project a number of antigens have or are being made including nm23, p53; Her2/neu is in the process of being produced, and an additional antigen, glycosylated whole human MUC1, is in the process of being engineered and produced. Although the original application cited cytotoxicity as the mode of testing, we have been busy establishing an ELISPOT assay and can distinguish between gammaIFN production by CD4 and CD8 cells. Immunisation methods have been refined, targeting the mannose receptor is being compared with various prime boost strategies and a new mode of immunisation has been designed. Progress is satisfactory and we are poised to push ahead with the studies in years 02 and 03.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2000
- Accession Number
- ADA385205
Entities
People
- Ian Mckenzie